Statins: pharmacoeconomic aspects of the use of hmg-coa reductase inhibitors
Keywords:HMG-CoA reductase inhibitors, medicines, pharmaceutical market, affordability
Big hopes for reducing high mortality from cardiovascular diseases are placed on statins, the use of which is due to the effective action of the drugs, broad indications, a prolonged and positive experience of use, and a high evidence base.
Purpose. The aim of the work was the formation of a modern understanding of the market structure and analysis of the availability of HMG-CoA reductase inhibitors.
Materials and methods. The studies were conducted in accordance with the State Register of Medicinal Products of Ukraine, ATC-classification, Equalizer system data. The study was performed by statistical, logical and graphical methods, as well as methods of marketing analysis.
Results. The paper analyzes the range, cost of daily doses of drugs, physical and economic accessibility of HMG-CoA reductase inhibitors. It was determined that the market is import-dependent - the share of domestic drugs is about 35%. The drugs are structured according to the ABC classification, the leading drugs are defined. The economic and physical accessibility of the HMG-CoA reductase inhibitors, which generally indicates their high and medium availability in the pharmaceutical market of Ukraine, was analyzed.
Conclusions: Among the leaders − 9 medicines, only 2 of them - drugs of domestic production, which indicates the possibility of developing a program for the import substitution of this particular group of drugs. Depending on the INN and the manufacturer, the prices of drugs vary within very wide limits, which makes it possible to choose a drug based on its affordability.
Statystyka aterosklerozu. (n.d.). Available at: http://surgeryzone.net/info/obshhemedicinskaya-informaciya/statistika-ateroskleroza.html
Tkachova, O. V. & Bogatirchuk, L. P. (2016). Suchasni napriamky udoskonalennia farmatsevtychnoho zabezpechennia naselennia na rehionalnomu rivni: materialy naukovoi-praktychnoi konferentsii (10-11. 05. 2016). Ivano-Frankivsk, 35–43.
Nemchenko, A. & Kurilenko, Ju. (2017). Aktualni problemy rozvytku haluzevoi ekonomiky ta lohistyky : materialy V naukovo-praktychnoi konferentsii z mizhnarodnoiu uchastiu (20-21. 04. 2017). Kharkiv, 410–411.
Iakovlieva, L. V., Mishchenko, O. Y., & Adonkina, V. Y. (2015). Calcium channel blockers: the study of the assortment, socio-economic affordability and volumes of consumption in Ukraine. Socìalʹna farmacìâ v ohoronì zdorov’â, 1(1), 18–24. https://doi.org/10.24959/sphhcj.15.3
Dumenko, T. M., Parіj, V. D., Jakovleva, L. V. & Zіmenkovs'kіj, A. B. (2013). Farmakoekonomika v Ukraini: stan ta perspektyvy rozvytku: materialy VI naukovo-praktychnoi konferentsii ( 22. 11. 2013). Kharkiv: NFaU, 180–281.
Kazak, L. І., Doroshenko, A. M., Djachenko, V. Ju., Zahorodnyi, M. I., Replianchuk, N. D. (2015). Racional'naja farmakoterapija, 1 (34). 36–38.
Malay, L. N. (2014). Statins in the treatment and prevention of cardiovascular diseases: repetition of the past and optimism for the future. Rational Pharmacotherapy in Cardiology, 10(5), 513–524. https://doi.org/10.20996/1819-6446-2014-10-5-513-524
Bezdіtko, N. V., Mіshhenko, O. Ja. & Chinush І. V. (2014). Klìnìčna farmacìâ, 2, 62–65.
ATC/DDD Index 2016 [ATC/DDD Index 2016]. – Available at: http://www.whocc.no/atc_ddd_index
Guidelines for ATC classification and DDD assignment. 16-th ed. (2012). WHO Collaborating Centre for Drug Statistics Methodology. Oslo.
Baza danih «Ekvalajzer» TOV «Bіznes-Kredit». (n.d.). Available at: http://eq.bck.com.ua
Kompendium: lekarstvennye preparaty. (n.d). Available at: http://compendium.com.ua/
Derzhavnyi reiestr likarskykh zasobiv Ukrainy. (n.d). Available at: http://www.drlz.com.ua
Copyright (c) 2019 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).